Biocure Enters into a Clinical Trial for CAR T -Cell Products in Korea

Vancouver, British Columbia--(Newsfile Corp. - October 17, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the "Company" or "Biocure") is pleased to announce that Biocure Pharm Corp.("BPK"), a subsidiary of the Company has appointed CLIPS (Clinical Professional Services) as the CRO (Contract Research Organization) to proceed with a Clinical Trial for CAR-T products in Korea. After reviewing multiple competent CRO's in Korea and multiple meetings with them, BPK has selected CLIPS who has outstanding experience as well as expertise in gene therapies and cell therapies. In addition, their knowledge on the clinical trials convinced BPK it could achieve a successful clinical trial for CAR-T products within the given timeline.

Dr. Sang Mok Lee, a CEO and President of Biocure as well as BPK states, "I am pleased to appoint CLIPS as our CRO to proceed to a clinical trial for CAR-T products in Korea, where our Company targets the first commercialization of our CAR-T products. Biocure has successfully completed there pre-clinical trial in Korea last October 2018 and now is fully geared to speed up the process of clinical trial in Korea through this CRO appointment. We should be able to start a clinical trial in Korea no later than January 2020 and in Germany within 2Q, 2020. Biocure will continue to make every effort to commercialize CAR-T products as soon as possible to meet the expectations of our shareholders."

About Biocure

Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis ("MS") Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine and a hair growth production product.

ON BEHALF OF THE BOARD OF DIRECTORS

/s/ "Sang Mok Lee"
CEO and Director

For further information, please contact: 
Biocure Technology Inc. Telephone: 604-609-7146, or info@biocuretech.com

Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company's proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the "CSE") nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48856

info